<DOC>
	<DOCNO>NCT00589316</DOCNO>
	<brief_summary>This phase I trial study side effect best dose iodine I 131monoclonal antibody BC8 give together fludarabine phosphate , cyclophosphamide , total-body irradiation , donor bone marrow transplant , see well work treat patient acute myeloid leukemia acute lymphoblastic leukemia spread nearby place body ( advanced ) , high-risk myelodysplastic syndrome . Giving chemotherapy drug , fludarabine phosphate cyclophosphamide , total-body irradiation donor bone marrow transplant help stop growth cancer abnormal cell help stop patient 's immune system reject donor 's stem cell . Also , radiolabeled monoclonal antibody , iodine I 131 monoclonal antibody BC8 , find cancer cell carry cancer-killing substance without harm normal cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving cyclophosphamide together mycophenolate mofetil tacrolimus transplant may stop happen . Giving radiolabeled monoclonal antibody together donor stem cell transplant , fludarabine phosphate , cyclophosphamide , mycophenolate mofetil , tacrolimus may effective treatment advance acute myeloid leukemia , acute lymphoblastic leukemia , myelodysplastic syndrome .</brief_summary>
	<brief_title>Iodine I 131 Monoclonal Antibody BC8 , Fludarabine Phosphate , Cyclophosphamide , Total-Body Irradiation Donor Bone Marrow Transplant Treating Patients With Advanced Acute Myeloid Leukemia , Acute Lymphoblastic Leukemia , High-Risk Myelodysplastic Syndrome</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate maximum tolerate dose radiation deliver via 131 I-BC8 antibody ( iodine I 131 monoclonal antibody BC8 ) combine pre- post-transplant cyclophosphamide ( CY ) , fludarabine phosphate ( FLU ) , 2 Gy total-body irradiation ( TBI ) , tacrolimus , mycophenolate mofetil ( MMF ) , haploidentical allogeneic hematopoietic marrow transplant patient advance acute myeloid leukemia ( AML ) , acute lymphoblastic leukemia ( ALL ) , high risk myelodysplastic syndrome ( MDS ) . II . To estimate rate immune reconstitution , engraftment , donor chimerism result combine preparative regimen . III . To determine rate disease relapse , acute graft-versus-host disease ( GVHD ) , day 100 disease-free survival patient receive 131 I-BC8 antibody ( Ab ) combine CY , FLU , 2 Gy TBI , tacrolimus , MMF , human leukocyte antigen ( HLA ) -haploidentical allogeneic hematopoietic cell transplant ( HCT ) . OUTLINE : This dose-escalation study iodine I 131 monoclonal antibody BC8 . RADIOIMMUNOTHERAPY : Patients receive therapeutic iodine I 131 monoclonal antibody BC8 via central line day -14 . NONMYELOABLATIVE CONDITIONING : Patients receive FLU intravenously ( IV ) 30 minute day -6 -2 CY IV 1 hour day -6 -5 . Patients undergo TBI day -1 . TRANSPLANTATION : Patients undergo allogeneic bone marrow transplantation day 0 . POST-TRANSPLATATION IMMUNOSUPPRESSION : Patients receive CY IV 1-2 hour day 3 , MMF IV orally ( PO ) thrice daily ( TID ) day 4 35 , tacrolimus IV 1-2 hour PO day 4 180 taper day 84 . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow 6 , 9 , 12 , 18 , 24 month , annually thereafter .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>Patients advance AML ALL define beyond first remission , primary refractory disease , evolve myelodysplastic myeloproliferative syndrome ; patient MDS express refractory anemia excess blast ( RAEB ) , refractory cytopenia multilineage dysplasia ( RCMD ) , RCMD ring sideroblast ( RCMDRS ) , chronic myelomonocytic leukemia ( CMML ) Patients remission must cluster differentiation ( CD ) 45expressing leukemic blast ; patient remission require phenotyping may leukemia previously document CD45 negative ( remission patient , virtually antibody bind nonmalignant cell make &gt; = 95 % nucleated cell marrow ) Patients circulate blast count le 10,000/mm^3 ( control hydroxyurea similar agent allow ) Patients must creatinine clearance great 50/ml per minute follow formula ( test must perform within 28 day prior registration ) : Creatinine clearance ( CrCl ) = ( 140age ) ( Wt Kg ) x 0.85 ( female ) OR 1.0 ( male ) /72 x serum Cr Bilirubin &lt; 2 time upper limit normal Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2 time upper limit normal Karnofsky score &gt; = 70 Eastern Cooperative Oncology Group ( ECOG ) = &lt; 2 Patients must expect survival &gt; 60 day must free active infection Patients must relate donor identical one human leukocyte antigen ( HLA ) haplotype mismatch HLAA , B class II , DR beta 1 ( DRB1 ) locus unshared haplotype exception single HLAA , B DRB1 mismatch DONOR : Related donor identical one HLA haplotype mismatch HLAA , B , DRB1 locus unshared haplotype exception single HLAA , B , DRB1 mismatch Circulating antibody mouse immunoglobulin ( HAMA ) Prior radiation maximally tolerated level critical normal organ Crossmatch positive donor Patients may symptomatic coronary artery disease may cardiac medication antiarrhythmic inotropic effect Left ventricular ejection fraction &lt; 35 % Corrected diffusion capacity carbon monoxide ( DLCO ) &lt; 35 % and/or receive supplemental continuous oxygen Liver abnormality : fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evidence prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis , symptomatic biliary disease Patients know seropositive human immunodeficiency virus ( HIV ) Perceived inability tolerate diagnostic therapeutic procedure , particularly treatment radiation isolation Central nervous system ( CNS ) involvement disease refractory intrathecal chemotherapy and/or standard cranialspinal radiotherapy Women childbearing potential pregnant ( betahuman chorionic gonadotropin positive [ bHCG+ ] ) breast feed Fertile men woman unwilling use contraceptive 12 month posttransplant Inability understand give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>